These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 30979348)
1. Neo-adjuvant therapy for pancreatic cancer: hope for the future. Borazanci E; Sckolnik S; Amini A Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):579-589. PubMed ID: 30979348 [TBL] [Abstract][Full Text] [Related]
2. Perspectives in the treatment of pancreatic adenocarcinoma. Cid-Arregui A; Juarez V World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356 [TBL] [Abstract][Full Text] [Related]
3. Update on the management of pancreatic cancer: surgery is not enough. Ansari D; Gustafsson A; Andersson R World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920 [TBL] [Abstract][Full Text] [Related]
5. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723 [TBL] [Abstract][Full Text] [Related]
6. Nodal downstaging as a treatment goal for node-positive pancreatic cancer. Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009 [TBL] [Abstract][Full Text] [Related]
7. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Badiyan SN; Molitoris JK; Chuong MD; Regine WF; Kaiser A Surg Oncol Clin N Am; 2017 Jul; 26(3):431-453. PubMed ID: 28576181 [TBL] [Abstract][Full Text] [Related]
8. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022 [TBL] [Abstract][Full Text] [Related]
9. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis. Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114 [TBL] [Abstract][Full Text] [Related]
10. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211 [TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. McGuigan A; Kelly P; Turkington RC; Jones C; Coleman HG; McCain RS World J Gastroenterol; 2018 Nov; 24(43):4846-4861. PubMed ID: 30487695 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma. Tesfaye AA; Philip PA Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899 [TBL] [Abstract][Full Text] [Related]
13. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment. Winer LK; Cortez AR; Ahmad SA; Wima K; Olowokure O; Latif T; Kharofa J; Patel SH J Surg Res; 2021 Mar; 259():442-450. PubMed ID: 33059910 [TBL] [Abstract][Full Text] [Related]
14. Optimal timing and treatment strategy for pancreatic cancer. Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic options for the management of pancreatic cancer. Rossi ML; Rehman AA; Gondi CS World J Gastroenterol; 2014 Aug; 20(32):11142-59. PubMed ID: 25170201 [TBL] [Abstract][Full Text] [Related]
16. Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapy. Baugh KA; Tran Cao HS; van Buren G; Silberfein EJ; Hsu C; Chai C; Barakat O; Fisher WE; Massarweh NN Surgery; 2019 Feb; 165(2):307-314. PubMed ID: 30243481 [TBL] [Abstract][Full Text] [Related]
17. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. Amin S; Baine M; Meza J; Lin C BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy in pancreatic cancer. Jones OP; Melling JD; Ghaneh P World J Gastroenterol; 2014 Oct; 20(40):14733-46. PubMed ID: 25356036 [TBL] [Abstract][Full Text] [Related]
19. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN). McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698 [TBL] [Abstract][Full Text] [Related]
20. The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis. Li Y; Liu W; Zhao L; Xu Y; Yan T; Yang Q; Pei Q; Güngör C Med Sci Monit; 2020 May; 26():e921515. PubMed ID: 32358953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]